Cargando…

Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory

In the last few months, an unprecedented number of laboratory tests for coronavirus disease 2019 (COVID‐19) have been developed at a remarkable speed. With the rapid adoption of these tests into clinical practice, combined with the widespread publicity they received, questions arose related to the d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xuemei, Markensohn, Julia F., Wollensak, David A., Laterza, Omar F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300945/
https://www.ncbi.nlm.nih.gov/pubmed/32475012
http://dx.doi.org/10.1111/cts.12828
_version_ 1783547608147427328
author Zhao, Xuemei
Markensohn, Julia F.
Wollensak, David A.
Laterza, Omar F.
author_facet Zhao, Xuemei
Markensohn, Julia F.
Wollensak, David A.
Laterza, Omar F.
author_sort Zhao, Xuemei
collection PubMed
description In the last few months, an unprecedented number of laboratory tests for coronavirus disease 2019 (COVID‐19) have been developed at a remarkable speed. With the rapid adoption of these tests into clinical practice, combined with the widespread publicity they received, questions arose related to the different types of tests, their utility, performance, and regulatory approval status. The aim of this publication is to provide a general landscape of laboratory testing for COVID‐19 and offer a historical and regulatory perspective associated with them. Specifically, we aim to elaborate on the regulatory complexities of diagnostic testing in the United States and its implications to the present outbreak, as well as provide a synopsis of laboratory tests that have been developed for COVID‐19. We will first address the detection of severe acute respiratory syndrome‐coronavirus 2 directly by either nucleic acid amplification tests or by the detection of the viral protein for active infections. Subsequently, we will provide an overview of serological tests that can aid not only in diagnosis but additionally help to identify prior infections and potential immunity.
format Online
Article
Text
id pubmed-7300945
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73009452020-06-18 Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory Zhao, Xuemei Markensohn, Julia F. Wollensak, David A. Laterza, Omar F. Clin Transl Sci Reviews In the last few months, an unprecedented number of laboratory tests for coronavirus disease 2019 (COVID‐19) have been developed at a remarkable speed. With the rapid adoption of these tests into clinical practice, combined with the widespread publicity they received, questions arose related to the different types of tests, their utility, performance, and regulatory approval status. The aim of this publication is to provide a general landscape of laboratory testing for COVID‐19 and offer a historical and regulatory perspective associated with them. Specifically, we aim to elaborate on the regulatory complexities of diagnostic testing in the United States and its implications to the present outbreak, as well as provide a synopsis of laboratory tests that have been developed for COVID‐19. We will first address the detection of severe acute respiratory syndrome‐coronavirus 2 directly by either nucleic acid amplification tests or by the detection of the viral protein for active infections. Subsequently, we will provide an overview of serological tests that can aid not only in diagnosis but additionally help to identify prior infections and potential immunity. John Wiley and Sons Inc. 2020-06-29 2020-09 /pmc/articles/PMC7300945/ /pubmed/32475012 http://dx.doi.org/10.1111/cts.12828 Text en © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society of Clinical Pharmacology & Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Zhao, Xuemei
Markensohn, Julia F.
Wollensak, David A.
Laterza, Omar F.
Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory
title Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory
title_full Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory
title_fullStr Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory
title_full_unstemmed Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory
title_short Testing For SARS‐CoV‐2: The Day the World Turned its Attention to the Clinical Laboratory
title_sort testing for sars‐cov‐2: the day the world turned its attention to the clinical laboratory
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300945/
https://www.ncbi.nlm.nih.gov/pubmed/32475012
http://dx.doi.org/10.1111/cts.12828
work_keys_str_mv AT zhaoxuemei testingforsarscov2thedaytheworldturneditsattentiontotheclinicallaboratory
AT markensohnjuliaf testingforsarscov2thedaytheworldturneditsattentiontotheclinicallaboratory
AT wollensakdavida testingforsarscov2thedaytheworldturneditsattentiontotheclinicallaboratory
AT laterzaomarf testingforsarscov2thedaytheworldturneditsattentiontotheclinicallaboratory